American Century Companies Inc. Has $9.79 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

American Century Companies Inc. increased its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 480,529 shares of the company's stock after acquiring an additional 29,155 shares during the quarter. American Century Companies Inc. owned about 0.33% of Denali Therapeutics worth $9,793,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of DNLI. Yiheng Capital Management L.P. lifted its holdings in shares of Denali Therapeutics by 16.7% during the fourth quarter. Yiheng Capital Management L.P. now owns 700,098 shares of the company's stock valued at $14,268,000 after acquiring an additional 100,000 shares during the period. Teacher Retirement System of Texas increased its position in Denali Therapeutics by 18.6% in the fourth quarter. Teacher Retirement System of Texas now owns 38,178 shares of the company's stock worth $778,000 after purchasing an additional 5,987 shares during the period. Intech Investment Management LLC raised its stake in shares of Denali Therapeutics by 60.4% during the fourth quarter. Intech Investment Management LLC now owns 47,401 shares of the company's stock worth $966,000 after buying an additional 17,858 shares during the last quarter. Cibc World Markets Corp acquired a new position in Denali Therapeutics in the fourth quarter valued at approximately $237,000. Finally, Swiss National Bank grew its holdings in Denali Therapeutics by 1.1% during the 4th quarter. Swiss National Bank now owns 253,500 shares of the company's stock worth $5,166,000 after acquiring an additional 2,800 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Denali Therapeutics news, Director Steve E. Krognes sold 3,339 shares of the company's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the transaction, the director now directly owns 25,757 shares in the company, valued at $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 7.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on DNLI. William Blair restated an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $31.00 target price for the company. Oppenheimer decreased their price objective on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. B. Riley reaffirmed a "buy" rating and issued a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Finally, Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price objective for the company. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.20.

Denali Therapeutics Stock Down 1.5 %

Shares of NASDAQ DNLI traded down $0.18 during trading hours on Monday, hitting $11.60. The company had a trading volume of 1,709,607 shares, compared to its average volume of 1,062,572. The stock has a market capitalization of $1.68 billion, a P/E ratio of -4.20 and a beta of 1.58. Denali Therapeutics Inc. has a 1-year low of $10.58 and a 1-year high of $33.33. The firm's 50 day moving average is $17.83 and its 200-day moving average is $22.46.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. On average, sell-side analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.